
GeneThera Inc. Stock Analysis GTHR
GeneThera is a biotechnology company, dedicated to improving food safety by applying the latest molecular technologies to eradicate ''cross over''(zoonotic) diseases such as Johne's Disease, Mad Cow Disease, Chronic Wasting Disease, and E.coli. The company is headquartered in Westminster, Colorado and currently employs 2 full-time employees. The firm is focused on developing genetics-based diagnostic assays and vaccine solutions and molecular diagnostic tests, therapeutics, and vaccines through its technologies for controlling the spread of zoonotic infection. The firm has developed a Molecular Robotic/AI Laboratory Platform (MORAP), which combine the use of advanced robotic laboratory systems integrated with artificial intelligence software systems. Its MORAPAT is designed to prevent the spread of disease from animals and control zoonotic infectious agents. The firm has also developed a large-scale process for highly purified and high viral titer (viral concentration) Adenovirus and Adeno-associated virus (AAV) genetically engineered viruses. This technology develops Adenovirus and AAV-based recombinant DNA vaccines for zoonotic pathogens. PURIVAX is a purification system that enhances biological purity and viral titer of recombinant Adenovirus and AAV vectors.
Read More GeneThera Inc (GTHR) Chart
Key Statistics of GeneThera Inc (GTHR)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
-P/E Ratio (TTM)
-52 Week Range
Market Cap
3533.00Avg. Volume
-Dividend Yield
-Financial Metrics & Statements of GeneThera Inc (GTHR)
FAQ's for GeneThera Inc (GTHR)
- According to Musaffa’s Shariah screening methodology, GeneThera Inc (GTHR) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.